# CRADD

## Overview
CRADD, also known as RAIDD, is a gene that encodes the CASP2 and RIPK1 domain containing adaptor with death domain, a crucial adaptor protein involved in apoptotic signaling pathways. This protein is characterized by its caspase activation and recruitment domain (CARD) and death domain (DD), which facilitate its role in forming the PIDDosome complex, essential for caspase-2-mediated apoptosis. CRADD is primarily located in the cytoplasm, where it acts as a bipartite linker, connecting caspase-2 and PIDD1, thereby playing a significant role in the DNA damage response and cellular homeostasis. Mutations in the CRADD gene have been associated with neurodevelopmental disorders, such as thin lissencephaly, highlighting its importance in normal brain development and function (Di2016Mutations; Sladky2017The; Puffenberger2012Genetic).

## Structure
The CRADD protein, also known as RAIDD, is characterized by two key domains: the caspase activation and recruitment domain (CARD) and the death domain (DD). The CARD domain is located at the N-terminal, spanning amino acids 1-92, while the DD is situated at the C-terminal, covering amino acids 116-188 (Di2016Mutations; Koprulu2021CRADD). These domains are crucial for CRADD's role in apoptotic signaling, facilitating interactions with proteins such as PIDD and caspase-2 to form the PIDDosome complex, which is essential for caspase-2-mediated apoptosis (Di2016Mutations; Puffenberger2012Genetic).

Mutations within the CRADD gene, particularly in the DD, can affect its interaction with PIDD and caspase-2, leading to impaired neuronal apoptosis and associated developmental disorders (Di2016Mutations; Puffenberger2012Genetic). The p.Gly128Arg mutation, for instance, disrupts the interaction surfaces of the DD, altering its binding affinity and localization (Puffenberger2012Genetic). Despite these mutations, the CARD domain remains largely unaffected, maintaining its structural integrity (Koprulu2021CRADD). The secondary structure predictions indicate differences in mRNA hairpin and stem-loop formations between wild-type and variant CRADD, though the overall stability remains similar (Koprulu2021CRADD).

## Function
CRADD, also known as RAIDD, is a crucial adaptor protein involved in apoptotic signaling pathways. It functions primarily in the cytoplasm, where it facilitates the formation of the Caspase-2-PIDDosome complex, a multi-protein assembly that plays a significant role in the DNA damage response and apoptosis. CRADD acts as a bipartite linker within this complex, connecting caspase-2 and PIDD1 through its death domain and caspase-recruitment domain (CARD) (Sladky2017The).

The interaction between CRADD and caspase-2 is essential for the activation of caspase-2, which is a critical step in the induction of apoptosis. This process is vital for maintaining cellular homeostasis by eliminating damaged or unwanted cells, thereby preventing the accumulation of potentially harmful mutations (Sladky2017The).

CRADD's role extends to the regulation of inflammation, as it is involved in the formation of complexes that respond to DNA damage and other cellular stressors. These interactions highlight CRADD's importance in both cell death regulation and the broader DNA damage response, contributing to the maintenance of genomic stability (Sladky2017The).

## Clinical Significance
Mutations in the CRADD gene are associated with several neurodevelopmental disorders, primarily characterized by intellectual disability and lissencephaly, a condition marked by a smooth brain surface due to abnormal neuronal migration. A specific variant of lissencephaly linked to CRADD mutations is thin lissencephaly (TLIS), which is characterized by megalencephaly, frontal predominant pachygyria, intellectual disability, and seizures (Di2016Mutations). These mutations lead to reduced caspase-2-mediated neuronal apoptosis, a critical process for normal brain development, resulting in cortical malformations (Di2016Mutations).

The CRADD gene mutations, such as p.Gly128Arg, p.Phe164Cys, p.Arg170Cys, and p.Arg170His, cluster in the death domain of the CRADD protein, potentially disrupting its interaction with the PIDD-DD, which is essential for activating caspase-2 (Di2016Mutations). This disruption impairs neuronal apoptosis, contributing to the development of megalencephaly and TLIS (Di2016Mutations).

In addition to TLIS, CRADD mutations have been linked to other conditions, including brain atrophy, developmental delay, strabismus, behavioral problems, and skeletal anomalies (Koprulu2021CRADD). These findings underscore the critical role of CRADD in neurodevelopment and its potential impact on cognitive function and brain structure.

## Interactions
CRADD, also known as RAIDD, is involved in several protein interactions that play crucial roles in apoptotic and inflammatory signaling pathways. CRADD interacts with BCL10 through its caspase recruitment domain (CARD), which is significant in modulating the assembly of signaling complexes involved in immune responses. This interaction suppresses the formation of complexes between BCL10 and CARMA1, which are essential for T cell receptor (TCR)-coupled expression of cytokines under NF-κB control (Lin2012Cutting). CRADD's interaction with BCL10 is inducible and peaks at 2 hours post-activation with anti-CD3/CD28 antibodies, particularly in naive CD4+ T cells (Lin2012Cutting).

CRADD also forms part of the PIDDosome complex, interacting with PIDD1 and Caspase-2, which is involved in apoptosis following DNA damage. However, the loss of CRADD does not significantly impact tumor formation in various cancer models, suggesting that Caspase-2-mediated tumor suppression can occur independently of CRADD (Peintner2015The).

In endothelial cells, CRADD negatively regulates BCL10, a component of the CARMA3 signalosome, which is involved in the activation of the NF-κB pathway. This interaction is crucial for maintaining endothelial barrier function and modulating inflammatory responses (Qiao2014The).


## References


[1. (Koprulu2021CRADD) Mine Koprulu, Rana Muhammad Kamran Shabbir, Qamar Zaman, Gökhan Nalbant, Sajid Malik, and Aslıhan Tolun. Cradd and usp44 mutations in intellectual disability, mild lissencephaly, brain atrophy, developmental delay, strabismus, behavioural problems and skeletal anomalies. European Journal of Medical Genetics, 64(4):104181, April 2021. URL: http://dx.doi.org/10.1016/j.ejmg.2021.104181, doi:10.1016/j.ejmg.2021.104181. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2021.104181)

[2. (Lin2012Cutting) Qing Lin, Yan Liu, Daniel J. Moore, Sydney K. Elizer, Ruth A. Veach, Jacek Hawiger, and H. Earl Ruley. Cutting edge: the “death” adaptor cradd/raidd targets bcl10 and suppresses agonist-induced cytokine expression in t lymphocytes. The Journal of Immunology, 188(6):2493–2497, March 2012. URL: http://dx.doi.org/10.4049/jimmunol.1101502, doi:10.4049/jimmunol.1101502. This article has 12 citations.](https://doi.org/10.4049/jimmunol.1101502)

[3. (Sladky2017The) Valentina Sladky, Fabian Schuler, Luca L. Fava, and Andreas Villunger. The resurrection of the piddosome – emerging roles in the dna-damage response and centrosome surveillance. Journal of Cell Science, 130(22):3779–3787, November 2017. URL: http://dx.doi.org/10.1242/jcs.203448, doi:10.1242/jcs.203448. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.203448)

[4. (Puffenberger2012Genetic) Erik G. Puffenberger, Robert N. Jinks, Carrie Sougnez, Kristian Cibulskis, Rebecca A. Willert, Nathan P. Achilly, Ryan P. Cassidy, Christopher J. Fiorentini, Kory F. Heiken, Johnny J. Lawrence, Molly H. Mahoney, Christopher J. Miller, Devika T. Nair, Kristin A. Politi, Kimberly N. Worcester, Roni A. Setton, Rosa DiPiazza, Eric A. Sherman, James T. Eastman, Christopher Francklyn, Susan Robey-Bond, Nicholas L. Rider, Stacey Gabriel, D. Holmes Morton, and Kevin A. Strauss. Genetic mapping and exome sequencing identify variants associated with five novel diseases. PLoS ONE, 7(1):e28936, January 2012. URL: http://dx.doi.org/10.1371/journal.pone.0028936, doi:10.1371/journal.pone.0028936. This article has 250 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0028936)

[5. (Peintner2015The) L Peintner, L Dorstyn, S Kumar, T Aneichyk, A Villunger, and C Manzl. The tumor-modulatory effects of caspase-2 and pidd1 do not require the scaffold protein raidd. Cell Death &amp; Differentiation, 22(11):1803–1811, April 2015. URL: http://dx.doi.org/10.1038/cdd.2015.31, doi:10.1038/cdd.2015.31. This article has 19 citations.](https://doi.org/10.1038/cdd.2015.31)

[6. (Di2016Mutations) Nataliya Di Donato, Ying Y. Jean, A. Murat Maga, Briana D. Krewson, Alison B. Shupp, Maria I. Avrutsky, Achira Roy, Sarah Collins, Carissa Olds, Rebecca A. Willert, Agnieszka M. Czaja, Rachel Johnson, Jessi A. Stover, Steven Gottlieb, Deborah Bartholdi, Anita Rauch, Amy Goldstein, Victoria Boyd-Kyle, Kimberly A. Aldinger, Ghayda M. Mirzaa, Anke Nissen, Karlla W. Brigatti, Erik G. Puffenberger, Kathleen J. Millen, Kevin A. Strauss, William B. Dobyns, Carol M. Troy, and Robert N. Jinks. Mutations in cradd result in reduced caspase-2-mediated neuronal apoptosis and cause megalencephaly with a rare lissencephaly variant. The American Journal of Human Genetics, 99(5):1117–1129, November 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.09.010, doi:10.1016/j.ajhg.2016.09.010. This article has 48 citations.](https://doi.org/10.1016/j.ajhg.2016.09.010)

[7. (Qiao2014The) Huan Qiao, Yan Liu, Ruth A. Veach, Lukasz Wylezinski, and Jacek Hawiger. The adaptor cradd/raidd controls activation of endothelial cells by proinflammatory stimuli. Journal of Biological Chemistry, 289(32):21973–21983, August 2014. URL: http://dx.doi.org/10.1074/jbc.M114.588723, doi:10.1074/jbc.m114.588723. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M114.588723)